Sweden
· Delayed Price · Currency is SEK Stayble Therapeutics AB Statistics
Total Valuation
Stayble Therapeutics AB has a market cap or net worth of SEK 17.93 million. The enterprise value is 15.18 million.
| Market Cap | 17.93M |
| Enterprise Value | 15.18M |
Important Dates
The next estimated earnings date is Thursday, February 20, 2025.
| Earnings Date | Feb 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Stayble Therapeutics AB has 43.72 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 43.72M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.50% |
| Owned by Institutions (%) | 23.64% |
| Float | 40.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.97 |
| EV / Sales | 40.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.49, with a Debt / Equity ratio of 0.09.
| Current Ratio | 8.49 |
| Quick Ratio | 5.68 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -330.11 |
Financial Efficiency
Return on equity (ROE) is -96.03% and return on invested capital (ROIC) is -58.51%.
| Return on Equity (ROE) | -96.03% |
| Return on Assets (ROA) | -49.62% |
| Return on Capital (ROIC) | -58.51% |
| Revenue Per Employee | 188,000 |
| Profits Per Employee | -7.85M |
| Employee Count | 3 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.69% in the last 52 weeks. The beta is 0.26, so Stayble Therapeutics AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | +32.69% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 0.51 |
| Relative Strength Index (RSI) | 35.94 |
| Average Volume (20 Days) | 350,504 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Stayble Therapeutics AB had revenue of SEK 376,000 and -15.69 million in losses.
| Revenue | 376,000 |
| Gross Profit | 376,000 |
| Operating Income | -16.09M |
| Pretax Income | -15.69M |
| Net Income | -15.69M |
| EBITDA | n/a |
| EBIT | -16.09M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 3.59 million in cash and 850,000 in debt, giving a net cash position of 2.74 million or 0.06 per share.
| Cash & Cash Equivalents | 3.59M |
| Total Debt | 850,000 |
| Net Cash | 2.74M |
| Net Cash Per Share | 0.06 |
| Equity (Book Value) | 9.89M |
| Book Value Per Share | n/a |
| Working Capital | 5.09M |
Cash Flow
| Operating Cash Flow | -20.29M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -4,280.49% |
| Pretax Margin | -4,173.40% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Stayble Therapeutics AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |